Baxter’s REVACLEAR Dialyzer May Offer New Benefits
A new study of 37,500 HD patient records found that use of a REVACLEAR high flux dialyzer was linked to the need for 100 to 600 fewer units of ESA per treatment than matched patients who used an Optiflux® 160 or 180 dialyzer. Researchers also noted a trend toward lower IV iron doses with the Revaclear—while keeping the same HD dose and hemoglobin level.
Read the full article » | Posted 08-09-2016
Related Articles
- Nephrologist Dr. Roberto Collazo Shares New Treatments for Kidney Disease and ESKD Posted 12-11-2024
- Ellen Lukens from CMMI Presents on the Kidney Care Choices Model Posted 12-11-2024
- 2025 NKF Survey on Kidney Health Priorities Finds Home Dialysis is a Patient Priority Posted 12-11-2024
- FDA Correction on Baxter MiniCap Extended Life PD Transfer Set Posted 12-11-2024